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Abstract 
Background: Current influenza vaccines need to be annually reformulated to well match the predicated circulating 
strains. Thus, it is critical for developing a novel universal influenza vaccine that would be able to confer cross-protec-
tion against constantly emerging divergent influenza virus strains. Influenza virus A is a genus of the Orthomyxoviri-
dae family of viruses. Influenza virus nucleoprotein (NP) is a structural protein which encapsidates the negative strand 
viral RNA, and anti-NP antibodies play role in cross-protective immunity. Lactococcus lactis (L. lactis) is an ideal vaccine 
delivery vehicle via oral administration route. However, L. lactis vectored vaccine exhibits poor immunogenicity with-
out the use of mucosal adjuvant. To enhance the immunogenicity of L. lactis vectored vaccine, cholera toxin B (CTB) 
subunit, one of mucosal adjuvants, is a safe adjuvant for oral route, when combined with L. lactis vectored vaccine. In 
this study, we hypothesized that pNZ8008, a L. lactis expression plasmid, encoding NP antigen, would be able to elicit 
cross-protection with the use of CTB via oral administration route.
Results: To construct L. lactis vectored vaccine, nucleoprotein (NP) gene of A/California/04/2009(H1N1) was sub-
cloned into a L. lactis expression plasmid, pNZ8008. The expression of recombinant L. lactis/pNZ8008-NP was con-
firmed by Western blot, immunofluorescence assay and flow cytometric analysis. Further, immunogenicity of L. 
lactis/pNZ8008-NP alone or adjuvanted with cholera toxin B (CTB) subunit was evaluated in a mouse model via oral 
administration route. Antibodies responses were detected by ELISA. The result indicated that oral administration of L. 
lactis/pNZ8008-NP adjuvanted with CTB could elicit significant humoral and mucosal immune responses, as well as 
cellular immune response, compared with L. lactis/pNZ8008-NP alone. To further assess the cross-protective immunity 
of L. lactis/pNZ8008-NP adjuvanted with CTB, we used L. lactis/pNZ8110-pgsA-HA1 alone or adjuvanted with CTB as 
controls. Mice that received L. lactis/pNZ8008-NP adjuvanted with CTB were completely protected from homologous 
H1N1 virus and showed 80% protection against heterologous H3N2 or H5N1 virus, respectively. By contrast, L. lactis/
pNZ8110-pgsA-HA1 adjuvanted with CTB also conferred 100% protection against H5N1 virus infection, but indicated 
no cross-protection against H1N1 or H5N1 virus challenge. As controls, mice vaccinated orally with L. lactis/pNZ8008-
NP alone or L. lactis/pNZ8110-pgsA-HA1 alone could not survive.
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Conclusion: This study is the first to report the construction of recombinant L. lactis/pNZ8008-NP and investigate its 
immunogenicity with the use of CTB. Compared with L. lactis/pNZ8110-pgsA-HA1 adjuvanted with CTB, our data sup-
port 5 × 1011 CFU of L. lactis/pNZ8008-NP adjuvanted with 1 µg of CTB is a better combination for universal influenza 
vaccines development that would provide cross-protective immunity against divergent influenza A viruses.
Keywords: L. lactis/pNZ8008-NP adjuvanted with CTB, Cross-protective immunity, Influenza A viruses
B subunit (CTB) via intranasal immunization in the 
mouse model, which indicated that 70–80% of mice were 
protected from homologous challenge with A/Puerto 
Rico/8/1934 (H1N1) and 40–70% of mice were protected 
from heterologous challenge [21]. However, most of 
effective approaches based on viral vectors, such as ade-
novirus [22] and baculovirus [21] expressing NP protein, 
are associated with potential safety issues [23].
Mucosal vaccination can provide the first line of 
defense against the entry of influenza virus. Thus, impor-
tant features of a novel influenza vaccine would be its 
capacity to induce strong mucosal immune response, as 
well as humoral and cellular immune responses [24–26]. 
Lactococcus lactis (L. lactis) is a Gram-positive bacterium 
and therefore does not possess endotoxic lipopolysac-
charides (LPS) [27]. Importantly, it is generally regarded 
as safe (GRAS) that is used for centuries in the food 
industry [27]. These features lead to L. lactis is suitable 
for mucosal immunization as a vaccine delivery platform. 
Our previous studies have reported that the HA1 protein 
of avian influenza H5N1 virus was displayed on L. lactis 
surface (L. lactis/pNZ8110-pgsA-HA1), mice co-vacci-
nated orally with recombinant L. lactis/pNZ8110-pgsA-
HA1 adjuvanted with CTB were completely protected 
from homologous H5N1 virus infection [19]. Further, we 
extended our work that intranasal vaccination of L. lactis-
HA adjuvanted with labile enterotoxin B (LTB) subunit 
could also confer 100% protection against homologous 
H5N1 virus infection in the chicken model [28]. How-
ever, influenza vaccines that provide heterotypic protec-
tion are the increasing concerns [1]. Due to NP protein 
has cross-reactivity and shows poor immunogenicity 
[12], we hypothesized that recombinant L. lactis express-
ing NP protein with the use of a mucosal adjuvant would 
be able to provide cross-protective immunity against 
divergent influenza A viruses.
To address this hypothesis, we investigated the immu-
nogenicity of L. lactis expressing NP protein adju-
vanted with a mucosal adjuvant, CTB, in a mouse 
model. Mice co-administered orally with recombinant L. 
lactis/pNZ8008-NP adjuvanted with CTB elicited signifi-
cant humoral and cellular immune responses, as well as 
mucosal immune response, compared with oral admin-
istration of L. lactis/pNZ8008-NP alone. In this study, 
H1N1, H3N2 and H5N1 are chosen for virus challenge, 
Background
Influenza A viruses have a great threat to public health 
concern and cause significant morbidity and mortal-
ity worldwide [1]. Seasonal influenza H1N1 and H3N2 
viruses cause an average of 3–5 million cases of severe 
illness and up to 250,000–500,000 deaths annually [2]. 
Additionally, World Health Organization (WHO) has 
reported that total of 666 cases infected with H5N1 caus-
ing 393 death in humans, since 2003 [3].
Vaccination is the most effective way to prevent and 
control influenza A viruses [1, 4]. Most of currently avail-
able influenza vaccines focus on the induction of neu-
tralizing antibodies that target the surface viral protein 
hemagglutinin (HA), which is subjected to a high degree 
of antigenic variation and new divergent strains continu-
ously arise in nature [5]. In this case, influenza vaccines 
need to be updated annually to well match the predicted 
virus strains [1]. Therefore, this brings out an urgent need 
for the development of an influenza vaccine that would 
be able to protect against the multiple antigenic variants.
It is well known that the development of a universal 
influenza vaccine relies on highly conserved regions of 
antigens [6, 7], such as the stalk domain of the HA [8, 
9], the amino terminus of the M2 proteins (M2e or M2 
ectodomain) [10] and the nucleoprotein (NP) [11]. Of 
note, phylogenetic analysis of virus strains isolated from 
different hosts indicates that the NP is relatively well 
conserved [12]. In addition, Influenza virus nucleopro-
tein (NP) is a structural protein which encapsidates the 
negative strand viral RNA [12]. Therefore, a highly con-
served NP protein is an attractive candidate for a broad-
spectrum influenza vaccine [7, 12–14]. Furthermore, the 
NP protein is the major target antigen for cytotoxic T 
lymphocyte (CTL) responses, and elicits cross-protective 
immunity to speed up viral clearance [15–18]. Usually, 
mucosal immunization (oral or intranasal) is not suf-
ficient for eliciting strong antibodies responses without 
the use of mucosal adjuvant. cholera toxin B (CTB) has 
been used successfully as a safe mucosal adjuvant with 
oral administration [19]. Importantly, CTB can stimu-
late upregulation on antigen-presenting cells (APCs) and 
promote Th2 immune responses [20]. To investigate the 
cross-protection of NP, Tamura et al., developed recom-
binant NP protein based on baculovirus expression sys-
tem, and then combined with the adjuvant cholera toxin 
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since they are generally used in developing influenza 
vaccine that provides cross-protection. Expectedly, L. 
lactis/pNZ8008-NP adjuvanted with CTB provided 
cross-protective immunity against homologous H1N1 
virus and heterologous H5N1 or H3N2 virus, compared 
with L. lactis/pNZ8110-pgsA-HA1 adjuvanted with CTB 
that showed complete protection against homologous 
H5N1 virus and no cross protection against heterologous 
H1N1 or H3N2 virus. Therefore, L. lactis/pNZ8008-NP 
adjuvanted with CTB is an ideal combination for devel-
oping a novel influenza vaccine that confers cross-pro-
tective immunity against divergent influenza A viruses.
Results
Construction of L. lactis vectored vaccine and expression 
of NP protein
Recombinant pNZ8008-NP plasmid was constructed 
(Fig.  1a). Expression of L. lactis/pNZ8008-NP was con-
firmed by Western blot analysis. A highly specific band 
(approximately 60  kDa) was observed in the L. lactis/
pNZ8008-NP cells (Fig. 1b, Lane 2), whereas, there was 
no specific band shown in the L. lactis/pNZ8008 cells 
(Fig. 1b, Lane 1).
To test intracellular expression level of the NP pro-
tein, L. lactis/pNZ8008-NP cells were examined by 
immunofluorescence assay and flow cytometry analysis. 
As shown in Fig.  1c, d, specific cell staining was clearly 
evident when L. lactis/pNZ8008-NP cells were reacted 
with polyclonal mouse anti-NP antibody, confirming that 
NP protein was expressed on L. lactis. In contrast, there 
were no specific fluorescence signals detected in the L. 
lactis/pNZ8008 cells.
Humoral and mucosal immune responses
NP—specific antibody responses were determined by 
ELISA. As shown in Fig.  2a, there were no significant 
sera IgG antibodies detected in all groups at day 16 
after the initial immunization. However, only mice vac-
cinated orally with L. lactis/pNZ8008-NP+CTB could 
produce highly significant IgG titers at day 33 after the 
initial immunization. By contrast, there were still no sig-
nificant changes in the PBS, L. lactis/pNZ8008, L. lactis/
pNZ8008+CTB or L. lactis/pNZ8008-NP group.
Mucosal IgA antibodies were also measured in the 
intestine and upper respiratory washes (Fig.  2b, c), 
respectively. There were no significant IgA antibodies in 
all groups after the prime immunization (at day 16). Only 
L. lactis/pNZ8008-NP adjuvanted with CTB induced a 
higher level of IgA antibodies after the boost immuniza-
tion (at day 33).
Collectively, these results demonstrate L. lactis/
pNZ8008-NP alone is poorly immunogenic. However, 
the immunogenicity of L. lactis/pNZ8008-NP could be 
highly enhanced by the use of mucosal adjuvant CTB. 
Fig. 1 Expression of NP protein on L. lactis. a Schematic diagram of recombinant pNZ8008-NP. b Western blot analysis. Lane 1 L. lactis/pNZ8008; 
Lane 2 L. lactis/pNZ8008-NP. c Immunofluorescence microscopy assay. L. lactis/pNZ8008 (left) and L. lactis/pNZ8008-NP (right) (magnification: 
×1,000). d Flow cytometric analysis. 10,000 events were recorded.
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Mice co-vaccinated orally L. lactis/pNZ8008-NP + CTB 
could produce significant NP-specific humoral immune 
responses, as well as mucosal immune responses.
Cellular immune responses elicited by L. lactis/
pNZ8008‑NP adjuvanted with CTB
To test the cellular immune responses, INF-γ and IL-4 
secreting cells were determined by ELISpot. As shown in 
Fig. 3, there were relatively low levels of INF-γ and IL-4 
in all groups at day 16 after the initial immunization. 
However, at day 33, oral co-administration of L. lactis/
pNZ8008-NP adjuvanted with CTB resulted in signifi-
cantly higher levels of INF-γ and IL-4 producing cells. 
Overall, these results indicate that L. lactis/pNZ8008-
NP adjuvanted with CTB can elicit significant cellular 
immune responses which include both Th1 and Th2 type 
immune responses with preferences of the Th1 immune 
responses.
Cross protection against virus challenge
To assess the cross protective immunity of L. lactis/
pNZ8008-NP adjuvanted with CTB, we used L. lactis/
pNZ8110-pgsA-HA1 adjuvanted with or without CTB 
as a control, all vaccinated mice were challenged with A/
California/04/2009(H1N1), A/Guangdong/08/95 (H3N2) 
or A/chicken/Henan/12/2004 (H5N1), and monitored 
for 14  days. Interestingly, mice that received L. lactis/
pNZ8110-pgsA-HA1+CTB showed a lower lung viral 
titer and slight weight loss against homologous H5N1 
virus. Whereas, higher viral titers and significant weight 
loss against heterologous H1N1 or H3N2 were observed 
in the L. lactis/pNZ8110-pgsA-HA1+CTB group. 
Fig. 2 Humoral and mucosal immune responses elicited by L. lactis/pNZ8008-NP+CTB.  a NP-specific IgG antibodies in the sera (n = 19 mice/
group); b NP-specific IgA antibodies in the intestine washes (n = 3 mice/group); c NP-specific IgA antibodies in the upper respiratory washes (n = 3 
mice/group). Data are indicated as mean ± standard deviation (SD). Asterisk (*) shows statistical significance compared with PBS, L. lactis/pNZ8008, 
L. lactis/pNZ8008+CTB or L. lactis/pNZ8008-NP controls (p < 0.05).
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Furthermore, L. lactis/pNZ8110-pgsA-HA1+CTB could 
provide 100% protection against homologous H5N1 
virus infection, and show no protection against heter-
ologous H1N1 or H3N2 virus challenge (Figs. 4, 5). The 
control groups that received PBS, L. lactis/pNZ8008 
alone, L. lactis/pNZ8008+CTB, L. lactis/pNZ8008-NP 
alone or L. lactis/pNZ8110-pgsA-HA1 alone started to 
develop significant body weight loss, a higher lung virus 
titer and died at days 6–8 post challenge (Figs.  4, 5). In 
contrast, mice vaccinated orally with L. lactis/pNZ8008-
NP + CTB were completely protected from homologous 
H1N1 virus challenge, and 80% protection against H3N2 
or H5N1 virus challenge. All survived mice in the L. lac-
tis/pNZ8008-NP+CTB group showed only mild weight 
loss, a lower lung virus titer and recovered by 14  days. 
Taken together, these results support that the immune 
responses induced by oral co-administration with L. 
lactis/pNZ8008-NP+CTB can confer cross-protection 
against divergent influenza A viruses in the mouse model.
Discussion
Existing influenza vaccines provide effective protection 
against virus infection, but they provide strain-specific 
protection and need to be updated annually [4].Thus, 
there is a clear need for developing a universal influenza 
vaccine that would broadly protect against several strains 
[9]. In this regard, the highly conserved NP of the influ-
enza A virus is an attractive candidate antigen for such 
a goal. Various systems have been applied to express NP 
protein [21–23, 29, 30], unfortunately, they show a lim-
ited cross-protection efficacy by intramuscular injection 
route. Mucosal administration represents an alternative 
approach to promote immune responses at the pathogen 
portal entry. The combination of a conserved influenza 
antigen with an efficient mucosal adjuvant could be a 
good approach to develop a universal influenza vaccine 
[21, 31, 32]. In this study, we chose L. lactis as a vaccine 
delivery vehicle, since it had a well-established safety pro-
file. An exclusive plasmid of L. lactis, pNZ8008, could 
stably express viral antigen on L. lactis. NP expressed on 
L. lactis has shown a wealth of information regarding its 
characterization that can be reacted with monoclonal 
anti-NP antibody showing positive signals for Western 
blotting, immunofluorescence assay and flow cytometric 
analysis (Fig. 1). These data provide a possibility that the 
immunogenicity of NP based on L. lactis expression sys-
tem can be further investigated via oral co-administra-
tion in the mouse model.
Increased serum levels of humoral immune responses 
were detected in mice vaccinated orally with L. lactis/
pNZ8008-NP and CTB was used as a mucosal adjuvant 
(Fig.  2a). Although NP-specific IgG antibodies have no 
neutralizing activity, their importance should be high-
lighted. Several studies have shown that NP-containing 
immune-complexes released from infected cells could 
bind to Fc receptors on dendritic cells, thereby enhanc-
ing antigen presentation and subsequent viral clearance 
[33, 34]. Based on these findings, it was suggested that 
the capacity to stimulate anti-NP IgG may be a critical 
feature of a universal influenza vaccine [33]. Our study 
further testified that NP-specific antibodies could sig-
nificantly contribute to protection against influenza virus 
infection.
Another prominent feature of L. lactis/pNZ8008-NP 
adjuvanted with CTB vaccine was the induction of signifi-
cant NP-specific IgA responses in upper respiratory and 
intestine washes. This is particularly important since the 
influenza virus is a respiratory pathogen, colonizing tra-
chea, bronchi and pulmonary alveoli as sites of viral repli-
cation [25]. It is tempting to speculate that this IgA might 
also contribute to cross-protection by a process known 
as intracellular neutralization which may play an impor-
tant role in heterosubtypic immunity. Secretory IgA can 
be internalized within epithelial cells by the polymeric 
immunoglobulin receptor which would prevent viral 
assembly and neutralize viral infection [35]. Furthermore, 
the strategy for NP as an antigen is based on the elicita-
tion of strong cell-mediated immunity rather than the 
induction of neutralizing antibodies [23]. In this study, 
an attractive feature of L. lactis/pNZ8008-NP adjuvanted 
with CTB is its extraordinary ability to induce a significant 
cellular response. Cytokine profiles of splenocytes from 
Fig. 3 Cellular immune responses. IFN-γand IL-4 secreting spots were 
determined by ELISpot (n = 3 mice/group). Data are represented as 
mean ± SD. Asterisk indicates significant difference compared with 
PBS, L. lactis/pNZ8008, L. lactis/pNZ8008 + CTB or L. lactis/pNZ8008-
NP controls (p < 0.05).
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mice orally co-immunized L. lactis/pNZ8008-NP adju-
vanted with CTB showed a secretion of INF-γ than IL-4 
(Fig.  3), thereby suggesting a Th1 dominating immune 
response which may contribute to cross-protection.
It is well recognized that intranasal or oral deliv-
ery of antigen alone may not induce sufficient antibody 
response [25, 26]. In most of cases, the use of adjuvant 
will significantly increase the immunogenicity of antigen 
via mucosal administration [26]. Up to now, LTB and 
CTB are two strongest mucosal adjuvants, and have 
been verified by several studies [19, 21, 28]. Our previous 
studies have shown that oral administration of L. lactis/
pNZ8110-pgsA-HA1 combined with 1 milligram of CTB 
provided protection against homologous H5N1 virus 
infection [19]. Although L. lactis/pNZ8110-pgsA-HA1 
adjuvanted with CTB could provide protection against 
Fig. 5 Percent survival. Two weeks after the last immunization, mice were intranasally infected with 20 µL of 104 EID50 of lethal dose of A/
California/04/2009(H1N1) (a), A/Guangdong/08/95 (H3N2) (b) or A/chicken/Henan/12/2004 (H5N1) (c). For a parallel experiment, L. lactis/
pNZ8110-pgsA-HA1 alone or adjuvanted with CTB was used as a control for virus challenge. 10 mice/group were used to record survival rate.
(See figure on previous page)
Fig. 4 Cross-protection against divergent influenza A viruses. The results are expressed in terms of percent body weight (a–c) and lung viral titers 
(d–f). For a parallel experiment, L. lactis/pNZ8110-pgsA-HA1 alone or adjuvanted with CTB was used as a control for virus challenge. Data for lung 
viral titers (n = 3 mice/group) are represented as mean ± SD. Asterisk indicates significant difference compared with PBS, L. lactis/pNZ8008, L. lactis/
pNZ8008+CTB, L. lactis/pNZ8008-NP or L. lactis/pNZ8110-pgsA-HA1 controls (p <  0.05).
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homologous H5N1 virus infection, it did not generate 
cross-protective immunity against heterologous H1N1 
or H3N2 virus (Figs. 4, 5). Our current studies suggested 
that 5 × 1011 CFU of L. lactis/pNZ8008-NP adjuvanted 
with 1 µg of CTB, an optimal dosage for oral administra-
tion, could protect 100% mice against homologous chal-
lenge with H1N1 and 80% of mice against heterologous 
challenge with H5N1 or H3N2 (Figs.  4, 5). This means 
that the combination of L. lactis/pNZ8008-NP adju-
vanted with CTB could provide the potential for the 
development of a novel universal influenza vaccine via 
oral co-administration route.
Taken together, the quality of the immune responses 
stimulated by oral co-administration with 5 × 1011 CFU 
of L. lactis/pNZ8008-NP adjuvanted with 1  µg of CTB 
vaccine was clearly demonstrated by the cross-protection 
against homologous and heterologous influenza virus 
challenge. This study clearly indicates that the immu-
nogenicity of L. lactis/pNZ8008-NP would be greatly 
enhanced by CTB, and L. lactis/pNZ8008-NP adjuvanted 
with CTB is a promising universal influenza vaccine, 
which should be exploited to develop innovative vaccines 
against seasonal and pandemic influenza.
Methods
Construction of recombinant L. lactis/pNZ8008‑NP
The NP gene (1,515  bp, GenBank: CY121683.1) of A/
California/07/2009(H1N1) was PCR-amplified using 
pcDNA3.1- NP (kindly provided by St. Jude Children’s 
Hospital, Memphis, TN, USA) as a template and using the 
following primers with Spe I or Hind III site underlined 
(forward primer: 5′ CGCACTAGTATGAGTGACATC-
GAAGCCATGC 3′, reverse primer: 5′ CCGAAGCTTT-
TAACTGTACTCCTCTGCATTGTC 3′). The resulting 
Spe I/Hind III fragment was sub-cloned into pNZ8008 
which was purchased from NIZO food research (Neth-
erlands), and then electroporated into competent L. lac-
tis NZ9000 which was a genetically modified host. The 
positive clone of L. lactis/pNZ8008-NP was selected as 
described previously [36]. L. lactis containing pNZ8008 
without encoding NP gene (L. lactis/pNZ8008) was used 
as a negative control for the following tests.
Western blot analysis
The expression of recombinant L. lactis/pNZ8008-NP 
was detected by Western blot analysis as described previ-
ously [36]. In a brief, 5 × 105 cells of L. lactis/pNZ8008-
NP pellets were mixed with 60 µl of 6 ×  loading buffer 
and boiled for 10  min, then run on SDS–polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred 
to nitrocellulose membrane (Bio-Rad, Hercules, Califor-
nia, USA). The membrane was blocked with 5% non-fat 
milk, and then incubated with a 1:500 polyclonal mouse 
anti-NP antibody (kindly provided by NIH Biodefense 
and Emerging Infections Research Resources Repository, 
Manassas, VA, USA), overnight at 4°C. Affinity-purified 
horseradish peroxidase (HRP)-conjugated anti-mouse 
IgG (Sigma-Aldrich Corporation, St. Louis, MO, USA) 
was used as second antibody. Finally, the proteins were 
visualized using enhanced chemiluminescence (ECL) 
reagents (GE Healthcare) according to the manufactur-
er’s instructions.
Immunofluorescence assay
5  ×  105 cells of L. lactis/pNZ8008-NP were fixed with 
4% paraformaldehyde for 10  min at room temperature 
(RT) and permeabilized with 0.2% Triton X-100 in PBS 
at RT for 10  min. The cells were subsequently blocked 
with 1% bovine serum albumin (BSA) in PBS for 30 min 
at RT, and then incubated with polyclonal mouse anti-NP 
antibody and followed by goat anti-mouse IgG antibody 
conjugated with fluorescein isothiocyanate (FITC) (R&D 
Systems, USA). Finally, the cells were visualized using a 
fluorescent Leica DM IL LED microscope (Leica, Wet-
zlar, Germany). L. lactis/pNZ8008 cells were used as neg-
ative controls.
Flow cytometry analysis
5  ×  105 cells of L. lactis/pNZ8008-NP pellets were 
washed with cold washing buffer (1% BSA and 0.1% 
sodium azide in PBS), and then resuspended with 1% 
formaldehyde solution in cold wash buffer and fixed at 
4°C in the darkness for 30 min, followed by incubation 
in 0.2% Triton X-100 in PBS for permeabilization at 37°C 
for 15  min. Following centrifugation, the cell pellet was 
resuspended in polyclonal mouse anti-NP antibody and 
incubated at 4°C for 30 min. The cells were washed and 
reacted with FITC-conjugated anti-mouse IgG second-
ary antibody at 4°C for 30 min in the dark. The stained 
cells were washed again and analyzed by flow cytometry 
analysis (BD FacsCalibur, San Jose, CA, USA).
Vaccine, animals, immunization and sample collection
Recombinant L. lactis/pNZ8008 and L. lactis/pNZ8008-
NP cells were adjusted to 1012 colony forming unit 
(CFU)/ml with sterile PBS, respectively. Specific patho-
genic free (SPF) female BALB/c mice of 6 to 8  weeks 
of age were purchased from SLC Company (Shanghai, 
China). CTB was purchased from Sigma Chemical Com-
pany (St. Louis, MO, USA).
The mice (n  =  25 per group) were vaccinated orally 
by a dosing needle with 500  µL of 1012 CFU/mL of L. 
lactis/pNZ8008 alone, L. lactis/pNZ8008-NP alone or 
adjuvanted with 1  µg of CTB on days 0, 1, 2 for prime 
immunization and days 17, 18, 19 for boost immuniza-
tion. The oral dosage is equal to 5 × 1011 CFU of L. lactis 
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vectored vaccine with or without 1  µg of CTB for each 
immunization. PBS was used as a negative control.
At day 16 and day 33 after the first immunization, 
blood samples were collected from the retro-orbital 
plexus. Sera were separated by centrifugation of blood at 
2,000×g for 10 min and stored at −20°C until use. Intes-
tines and upper respiratory (n = 3/group) were isolated 
from the vaccinated mice and washed with 500 µL sterile 
PBS, respectively, and stored at −20°C until use.
All animal immunizations were performed at biosafety 
level 2 (BLS-2) containment facilities complying with 
the Guidelines for Use and Care of Experimental Ani-
mals and were approved by the Animal Committee of the 
Institute of Nanchang University.
Enzyme–linked immunosorbent assay (ELISA)
The NP-specific antibodies regarding IgG titers in the 
sera and IgA titers in the intestine and upper respira-
tory washes were determined by enzyme-linked immu-
nosorbent assay (ELISA) using recombinant 2 µg/ml NP 
protein (kindly provided by NIH Biodefense and Emerg-
ing Infections Research Resources Repository, Manassas, 
VA, USA) as a coating antigen, as described previously 
[36]. End-point ELISA titers were expressed as the recip-
rocal of the highest sample dilution that yielded an OD 
≥2 times above the mean value of the blank.
ELIspot assay
To determine the levels of cellular immune responses, 
murine IFN-γ and IL-4 enzyme-linked immunospot 
(ELISPOT) kits (R&D Systems, USA) were used in this 
study, according to the manufacturer’s instructions. Sple-
nocytes were isolated from the vaccinated mice at day 16 
and day 33 after the initial immunization. Cells (5 × 105 
cells/well) were stimulated with 2 µg/ml of recombinant 
NP protein, and then incubated for 36 h at 37°C with 5% 
CO2. Cells were removed and the plates were processed 
according to the manufacturer’s instructions. Colored 
spots were counted with an ELISPOT reader (CTL S5 
Micro Analyzer) and analyzed using ImmunoSpot image 
analyzer software v3.2 (CTL ImmunoSpot analyzer, OH, 
USA).
Virus challenge
At day 35 after the initial immunization, all the vacci-
nated mice were challenged intranasally with 20 µL of 104 
EID50 of lethal dose of A/California/04/2009(H1N1), A/
Guangdong/08/95 (H3N2) or A/chicken/Henan/12/2004 
(H5N1) virus. The mice were monitored for 14 days and 
calculated with body weight loss and survival rate after 
post challenge. Lungs were isolated at day 5 post chal-
lenge. Virus challenge experiments must be strictly 
performed under the enhanced bio-safety level-3 
laboratory (BSL-3). For a parallel experiment, L. lactis/
pNZ8110-pgsA-HA1 alone or adjuvanted with CTB was 
used as a control for virus challenge [19]. Survival rate is 
less than 60% that was considered to be no significance.
Lung viral titers
Lungs (n  =  3 mice/group) were isolated at day 5 post 
challenge, as described previously [37]. In brief, 10-fold 
dilutions of lung homogenate supernatants were mixed 
with MEM including trypsin in 100 μL. Dilutions were 
added to 96-well U-bottom plates with 100 μL of Madin-
Darby Canine Kidney (MDCK) cells at 2.5  ×  106cells/
mL. The plate was incubated overnight at 37°C, and the 
medium was replaced with fresh MEM without trypsin. 
After 72 h incubation, 50 μL of 0.5% chicken red blood 
cells (CRBCs) was added to each well. The plate was incu-
bated for 1 h at room temperature and recorded hemag-
glutination afterwards to determine 50% tissue culture 
infective dose (TCID50). TCID50 was then calculated by 
the Reed-Muench formula.
Statistical analysis
The Student’s t test and one-way ANOVA were used for 
all statistical analyses. A p value less than 0.05 was con-
sidered to be significant.
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